Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Mereo BioPharma Group plcNASDAQ: MREO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 160.36M shares rose 2.2% year over year, behind the +5.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +9.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +5.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
160.36M+0.6% QoQ
Last fiscal yearDec 2025
159.42M+7.8% YoY
LTMMar 2026
159.92M+5.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year+7.8%——
3-year CAGR+9.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
159.42M USD
Year-over-year change
+7.8%
4-year CAGR
+8.1%

Weighted Avg Shares vs competitors

How MREO compares with its peers on the latest reported figures

  • MREO's LTM Mar 2026 weighted avg shares of 159.92M shares is the highest of the 11 companies compared; the peer median is 58.04M shares.
  • Its year-over-year change of +5.1% is the 8th highest of 10, against a peer median of +19.6%.
  • Over three fiscal years its annual growth of +9.7% compares with a peer median of +19.4%.
MREO Competitors Peer median
Weighted Avg Shares for MREO and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
IMMPImmutep LimitedFY2025145.58M +21.3%+19.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026104.77M +19.6%+13.7%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
CADLCandel Therapeutics, Inc.LTM Mar 202655.91M +73.2%+22.5%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
Peer median (excluding MREO) 58.04M+19.6%+19.4%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.